JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin reiterates a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintains a $114 price target.
May 23, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities reiterates a Market Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintains a $114 price target.
The reiteration of a Market Outperform rating by JMP Securities analyst Reni Benjamin indicates a positive outlook for Blueprint Medicines. The maintained $114 price target suggests that the stock has potential for growth in the short term. This news is directly related to BPMC and is important for investors, as it provides an updated perspective on the stock's potential performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100